These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 19405109)

  • 1. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology.
    McKnight R; Nassar A; Cohen C; Siddiqui MT
    Cancer Cytopathol; 2012 Aug; 120(4):223-9. PubMed ID: 22298472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
    Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
    Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
    Lin F; Abdallah H; Meschter S
    Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.
    Fujiwara M; Kwok S; Yano H; Pai RK
    Cancer Cytopathol; 2012 Aug; 120(4):230-7. PubMed ID: 22434791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
    Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
    Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
    Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
    Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
    Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
    Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
    Ibrahim TR; Abdel-Raouf SM
    Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
    Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
    Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
    Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
    Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?
    de Boer WB; Segal A; Frost FA; Sterrett GF
    Cancer; 2000 Oct; 90(5):273-8. PubMed ID: 11038423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel.
    Saleh HA; Aulicino M; Zaidi SY; Khan AZ; Masood S
    Diagn Cytopathol; 2009 Mar; 37(3):184-90. PubMed ID: 19170172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
    Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
    Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
    Anatelli F; Chuang ST; Yang XJ; Wang HL
    Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology.
    Saad RS; Luckasevic TM; Noga CM; Johnson DR; Silverman JF; Liu YL
    Diagn Cytopathol; 2004 Jan; 30(1):1-6. PubMed ID: 14696137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemical staining of fine-needle aspiration biopsies of the liver as a diagnostic tool for hepatocellular carcinoma.
    Johnson DE; Powers CN; Rupp G; Frable WJ
    Mod Pathol; 1992 Mar; 5(2):117-23. PubMed ID: 1374187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver.
    Gokden M; Shinde A
    Diagn Cytopathol; 2005 Sep; 33(3):166-72. PubMed ID: 16078249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].
    Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.